Market Intelligence, Clinical Progress, and High-Purity Reagents for GPCR-Targeted Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GPR55 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Assay Cell Line | GPR55 Lentivirus Premade Particles (or Stable Cell Line) Optimized for stable cell line generation. Retains native 7-TM GPCR conformation. |
View GPR55 Products |
| Gene Delivery | GPR55 Promise-ORF Full-length ORF, Sequence Verified. |
View GPR55 Products |
| Benchmark Ab | Anti-GPR55 Recombinant Antibody High purity (>95%), Endotoxin controlled. |
View GPR55 Products |
| Validator | GPR55 siRNA Set For knockdown verification in functional assays. |
View GPR55 Products |
| Off-Target Homolog (A) | CB1 (CNR1) Classical cannabinoid receptor for selectivity counter-screening. |
View CB1 Products |
| Off-Target Homolog (B) | CB2 (CNR2) Immune-modulating cannabinoid receptor; endocannabinoid system pathway overlap. |
View CB2 Products |
| Off-Target Homolog (C) | GPR35 Close homolog; essential for selectivity counter-screening. |
View GPR35 Products |
| Ligand Family Partner | LPA1 (LPAR1) Lysophospholipid receptor; ligand promiscuity assessment. |
View LPA1 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Conformation (7TM) | Lentivirus-mediated stable expression in host cells preserves native glycosylation and functional epitopes for Flow Cytometry & Calcium Flux. |
| Subfamily Off-target (CB1/CB2) & Homology (GPR35) | CB1/CB2 control cell lines, GPR35 protein panel, and specific antibodies available for rigorous selectivity screening. |
| Lack of Reliable Controls | Sequence Verified recombinant benchmark antibodies provided. |
| False Positives in Signaling Assays | Validatable via targeted siRNA sets included for specificity checks. |
| GPCR Internalization & Trafficking | High-titer lentivirus (>1x10^8 TU/mL) for consistent β-arrestin recruitment and endocytosis studies. |
| Cell Surface Expression Validation | High-titer lentivirus ensures uniform surface receptor density for quantitative FACS/IF. |
Live GPR55 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GPR55 therapeutics is intensifying. As a putative atypical cannabinoid receptor, GPR55 plays a critical role in the LPI (lysophosphatidylinositol) signaling axis, driving cancer cell proliferation, neuropathic pain, and inflammatory bowel disease (IBD). Major players are actively developing small molecule antagonists, biased agonists, and allosteric modulators. First-generation antagonists are entering Phase I for IBD and oncology, while next-generation R&D focuses on G-protein selective pathways (Gα12/13 vs. Gαq) to minimize CNS side effects associated with the cannabinoid system. Key known missense mutations (e.g., dbSNP rs3749073, rs34229723) may alter receptor function and should be considered in drug design.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Top-tier Pharma, Biotech Ventures | Neuropathic Pain, Oncology, IBD, Rheumatoid Arthritis | Calcium Flux / Beta-arrestin (Need stable cell lines via Lentivirus) |
| Biased Agonist | Specialized GPCR Platforms | Cancer (Pancreatic, Glioblastoma) | β-Arrestin vs. G-protein pathway selectivity (Need full-length functional receptor) |
| Allosteric Modulator | Academic Consortia | Metabolic Disorders | Orthosteric binding competition (Need high-purity ligand and receptor cells) |
| Monoclonal Antibodies | Emerging Startups | Solid Tumors (Pancreatic) | Conformational Binding (Need native cell-surface expression) |
| Combination Tx | Academic/Pharma Collabs | Refractory Cancers | Pathway Cross-talk Analysis (Need CB1/CB2 & GPR35 counter-screens) |
Key Mutations and Functional Insights
Known natural variants in GPR55 include dbSNP rs3749073 and rs34229723 (UniProt Q9Y2T6). These missense mutations may impact ligand binding or signaling kinetics, underscoring the need for sequence-verified reagents and mutation-specific assay panels in drug discovery.